Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

Trial ID or NCT#

NCT01268280

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).

Official Title

A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy

Eligibility Criteria

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Yuen So, MD, PhD
Yuen So, MD, PhD
Neuromuscular neurologist, Neurophysiologist
Professor of Neurology (Adult Neurology)

Contact us to find out if this trial is right for you.

Contact

Shirely Paulose
650-724-3792

View on ClinicalTrials.gov